Shahryar Khoshtinat Nikkhoi
Overview
Explore the profile of Shahryar Khoshtinat Nikkhoi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikkhoi S, Li G, Hatefi A
Front Oncol
. 2025 Feb;
14:1483884.
PMID: 39911822
This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a...
2.
Yang G, Nikkhoi S, Owji H, Li G, Massumi M, Cervelli J, et al.
Antibodies (Basel)
. 2024 Sep;
13(3.
PMID: 39311380
We previously reported the structure, affinity, and anticancer activity of a bivalent bispecific natural killer cell engager (BiKE) composed of one anti-CD16a VHH and one anti-HER2 VHH fused via a...
3.
Nikkhoi S, Yang G, Owji H, Grizotte-Lake M, Cohen R, Gil Gonzalez L, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38490714
Background: In a prior report, we detailed the isolation and engineering of a bispecific killer cell engager, referred to as BiKE:E5C1. The BiKE:E5C1 exhibits high affinity/specificity for the CD16a activating...
4.
Nikkhoi S, Heydarzadeh H, Vandavasi V, Yang G, Louro P, Polunas M, et al.
Immunol Res
. 2023 Aug;
72(1):103-118.
PMID: 37632647
In the past decade, various single-domain antibodies from llamas, also known as VHH or nanobody, have been discovered with applications in tumor imaging and cancer therapy. However, the potential application...
5.
Li G, Nikkhoi S, Hatefi A
Med Oncol
. 2023 Mar;
40(4):110.
PMID: 36862260
Cancer stem-like cells (CSCs) are believed to be responsible for cancer recurrence and metastasis. Therefore, a therapeutic approach is needed to eliminate both rapidly proliferating differentiated cancer cells and slow-growing...
6.
Nikkhoi S, Li G, Eleya S, Yang G, Vandavasi V, Hatefi A
Front Immunol
. 2023 Jan;
13:1039969.
PMID: 36685519
Introduction: The Fc region of monoclonal antibodies (mAbs) interacts with the CD16a receptor on natural killer (NK) cells with "low affinity" and "low selectivity". This low affinity/selectivity interaction results in...
7.
Shams N, Nikkhoi S, Gu Z, Rahbarizadeh F
Med Oncol
. 2022 Aug;
39(11):177.
PMID: 35999405
CD20 is a receptor expressed on B cells with anonymous functions. The receptor is the target of some food and drug administration (FDA) approved monoclonal antibodies (mAb), such as Rituximab...
8.
Aghaie Fard A, Tourani M, Heydari F, Nikkhoi S, Heydarzadeh H, Mehdiabdol M, et al.
Transfus Apher Sci
. 2021 Oct;
60(6):103285.
PMID: 34620563
The most promising therapy for leukemia is hematopoietic stem cell transplantation. Engraftment of HPSCs mainly depends on some factors such as adhesion molecules, including VLAs. This study tried to delineate...
9.
Banihashemi S, Rahbarizadeh F, Zavaran Hosseini A, Ahmadvand D, Nikkhoi S
Int Immunopharmacol
. 2021 Sep;
100:107927.
PMID: 34500284
Objective: One of the vital signaling pathways in cancer development and metastasis is mitogen-activated protein kinases (MAPKs). Bacillus anthracis Lethal Toxin (LT) is a potent MAPK signaling inhibitor. This toxin...
10.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Nikkhoi S
Front Oncol
. 2021 Apr;
11:627549.
PMID: 33869011
Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment...